Cargando…

Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints

BACKGROUND: Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jiaying, Ma, Xiaoxi, Zhang, Huiwei, Xiao, Zhenxu, Li, Ming, Wu, Jie, Ju, Zizhao, Chen, Li, Zheng, Li, Ge, Jingjie, Liang, Xiaoniu, Bao, Weiqi, Wu, Ping, Ding, Ding, Yen, Tzu-Chen, Guan, Yihui, Zuo, Chuantao, Zhao, Qianhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308642/
https://www.ncbi.nlm.nih.gov/pubmed/37381042
http://dx.doi.org/10.1186/s40035-023-00365-x
_version_ 1785066288053223424
author Lu, Jiaying
Ma, Xiaoxi
Zhang, Huiwei
Xiao, Zhenxu
Li, Ming
Wu, Jie
Ju, Zizhao
Chen, Li
Zheng, Li
Ge, Jingjie
Liang, Xiaoniu
Bao, Weiqi
Wu, Ping
Ding, Ding
Yen, Tzu-Chen
Guan, Yihui
Zuo, Chuantao
Zhao, Qianhua
author_facet Lu, Jiaying
Ma, Xiaoxi
Zhang, Huiwei
Xiao, Zhenxu
Li, Ming
Wu, Jie
Ju, Zizhao
Chen, Li
Zheng, Li
Ge, Jingjie
Liang, Xiaoniu
Bao, Weiqi
Wu, Ping
Ding, Ding
Yen, Tzu-Chen
Guan, Yihui
Zuo, Chuantao
Zhao, Qianhua
author_sort Lu, Jiaying
collection PubMed
description BACKGROUND: Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and positron emission tomography (PET) ATN biomarkers in subjects with cognitive complaints. METHODS: A hospital-based cohort of subjects with cognitive complaints with a concurrent blood draw and ATN PET imaging ((18)F-florbetapir for A, (18)F-Florzolotau for T, and (18)F-fluorodeoxyglucose [(18)F-FDG] for N) was enrolled (n = 137). The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances. RESULTS: Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort. Plasma p-tau181 level and PET standardized uptake value ratios of AT biomarkers showed a similarly excellent diagnostic performance for distinguishing between Aβ+ and Aβ− subjects. An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects. Additionally, glucose hypometabolism – along with elevated plasma neurofilament light chain level – was related to more severe cognitive impairment in Aβ− subjects. CONCLUSION: Plasma p-tau181, as well as (18)F-florbetapir and (18)F-Florzolotau PET imaging can be considered as interchangeable biomarkers in the assessment of Aβ status in symptomatic stages of AD. (18)F-Florzolotau and (18)F-FDG PET imaging could serve as biomarkers for the severity of cognitive impairment. Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00365-x.
format Online
Article
Text
id pubmed-10308642
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103086422023-06-30 Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints Lu, Jiaying Ma, Xiaoxi Zhang, Huiwei Xiao, Zhenxu Li, Ming Wu, Jie Ju, Zizhao Chen, Li Zheng, Li Ge, Jingjie Liang, Xiaoniu Bao, Weiqi Wu, Ping Ding, Ding Yen, Tzu-Chen Guan, Yihui Zuo, Chuantao Zhao, Qianhua Transl Neurodegener Research BACKGROUND: Gaining more information about the reciprocal associations between different biomarkers within the ATN (Amyloid/Tau/Neurodegeneration) framework across the Alzheimer’s disease (AD) spectrum is clinically relevant. We aimed to conduct a comprehensive head-to-head comparison of plasma and positron emission tomography (PET) ATN biomarkers in subjects with cognitive complaints. METHODS: A hospital-based cohort of subjects with cognitive complaints with a concurrent blood draw and ATN PET imaging ((18)F-florbetapir for A, (18)F-Florzolotau for T, and (18)F-fluorodeoxyglucose [(18)F-FDG] for N) was enrolled (n = 137). The β-amyloid (Aβ) status (positive versus negative) and the severity of cognitive impairment served as the main outcome measures for assessing biomarker performances. RESULTS: Plasma phosphorylated tau 181 (p-tau181) level was found to be associated with PET imaging of ATN biomarkers in the entire cohort. Plasma p-tau181 level and PET standardized uptake value ratios of AT biomarkers showed a similarly excellent diagnostic performance for distinguishing between Aβ+ and Aβ− subjects. An increased tau burden and glucose hypometabolism were significantly associated with the severity of cognitive impairment in Aβ+ subjects. Additionally, glucose hypometabolism – along with elevated plasma neurofilament light chain level – was related to more severe cognitive impairment in Aβ− subjects. CONCLUSION: Plasma p-tau181, as well as (18)F-florbetapir and (18)F-Florzolotau PET imaging can be considered as interchangeable biomarkers in the assessment of Aβ status in symptomatic stages of AD. (18)F-Florzolotau and (18)F-FDG PET imaging could serve as biomarkers for the severity of cognitive impairment. Our findings have implications for establishing a roadmap to identifying the most suitable ATN biomarkers for clinical use. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40035-023-00365-x. BioMed Central 2023-06-29 /pmc/articles/PMC10308642/ /pubmed/37381042 http://dx.doi.org/10.1186/s40035-023-00365-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Lu, Jiaying
Ma, Xiaoxi
Zhang, Huiwei
Xiao, Zhenxu
Li, Ming
Wu, Jie
Ju, Zizhao
Chen, Li
Zheng, Li
Ge, Jingjie
Liang, Xiaoniu
Bao, Weiqi
Wu, Ping
Ding, Ding
Yen, Tzu-Chen
Guan, Yihui
Zuo, Chuantao
Zhao, Qianhua
Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
title Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
title_full Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
title_fullStr Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
title_full_unstemmed Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
title_short Head-to-head comparison of plasma and PET imaging ATN markers in subjects with cognitive complaints
title_sort head-to-head comparison of plasma and pet imaging atn markers in subjects with cognitive complaints
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10308642/
https://www.ncbi.nlm.nih.gov/pubmed/37381042
http://dx.doi.org/10.1186/s40035-023-00365-x
work_keys_str_mv AT lujiaying headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT maxiaoxi headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT zhanghuiwei headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT xiaozhenxu headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT liming headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT wujie headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT juzizhao headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT chenli headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT zhengli headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT gejingjie headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT liangxiaoniu headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT baoweiqi headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT wuping headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT dingding headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT yentzuchen headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT guanyihui headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT zuochuantao headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT zhaoqianhua headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints
AT headtoheadcomparisonofplasmaandpetimagingatnmarkersinsubjectswithcognitivecomplaints